Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation

Trial Profile

Effects of Losartan and Antiretroviral Regimen Containing Raltegravir in Fibrosis Inflammation

Completed
Phase of Trial: Phase IV

Latest Information Update: 22 Jul 2017

At a glance

  • Drugs Losartan (Primary) ; Raltegravir (Primary) ; Efavirenz/emtricitabine/tenofovir-disoproxil-fumarate; Emtricitabine/tenofovir disoproxil fumarate
  • Indications HIV infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 18 Feb 2016 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Feb 2014 Planned End Date changed from 1 Jun 2013 to 1 Dec 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top